Pharma and a few penny stocks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
added a bunch of 24s and 25s today. Lowered my average from .0028. Accum for me for all of 2019 :)
Yes you were right. I am loading the boat. Did not expect to see these levels. This is a good thing for me as I just bought in yesterday at .0028 :)
30 million almost traded in the first hour
Now into strong hands :)
I disagree for now. I think we bounce back up for now. End of day could be tricky but many of us just got filled :)
My boat is about half full now. thanks for the cheaps LOL!!!!!
LOADING ALL DIPS. THANKS FOR THE CHEAP SHARES TODAY
I understand. I added a nice starter yesterday with the news as well. A few million to get my feet wet LOL
I just got in yesterday at .0028 So feeling good so far. I hope to keep adding below .003 for now. If this gets cooking I will push it up as we go. Same applies to all my investments. I buy at different levels when the stock needs a boost. GLTY
Wow. I am going to have to put your lame A$$ on mute. Crying like a little BISH all day long... Later Gator
LOL. He probably sold at .003 and trying to reload lower LOL!!!!!
Nice buy. This will pay out well in the future
Almost 9 million shares traded and we are slightly green. That is not how dilution works. We would be deep in the red if they were dumping heavily. LOL
Sounds like an attempt to get cheap shares. Good luck. :)
No doubt. Spring Break out of the way now I can focus again on the market LOL
Huge bid support. Ask looks thin.
MORNING :)
Yessssss
I agree. they just need exposure and also an interested party.. The patent is like GOLD
Agree. This nano tech is going to make this very valuable
Holy Cow!!!! Can I ask where you confirmed this?
HUGE
Sounds like Shark Tank could be in our future too with that list LOL
Rodan and Fields worth $550 million and they do not have this same technology or patent :)
Right I like the long window here. I can add slowly and get a good price as opposed to it popping tomorrow. I love buying in the Spring and holding into the next year. I did that for VRUS and it has panned out well. I expect to see a similar situation here
These products remind me of Rodan and Fields which currently is valued at 550 million. These products here however are cheaper and more people could purchase them. I just think this company needs more exposure and marketing and it will take off. settling in for the long haul.
A dime is a long way off but I am holding and buying. We need a strong upward push to get past a penny and then build. Let's see what happens
ABSOLUTELY LOVE THIS
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Denmark-based Vilacto Bio Inc. (OTC QB:VIBI) is happy to announce that the Canadian Intellectual Property Office (CIPO) has informed the Company that its patent application for LACTOACTIVE® will be issued in near future.
The Company has already filed and received patents covering LACTOACTIVE® in the US, Europe and Hong Kong. The Canadian patent, when issued, is expected to give the company greater scope to continue developing the LACTOACTIVE® compound and bolster its international IP ownership position.
The patent applications in Canada also cover the Company’s new compound, LACTOACTIVE iTHER®, a LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases. LACTOACTIVE iTHER® is expected to generate new revenue streams in addition to the company’s LACTOACTIVE®-based therapeutic skincare range.
“Vilacto Bio now is in a stronger position than ever to leverage the potential of LACTOACTIVE,” said Vilacto Bio CEO Gert Anderson.
The main active component of LACTOACTIVE® and LACTOACTIVE iTHER® is colostrum, a natural substance that Vilacto Bio has refined and processed into a potent nanoparticle concentrate. In NPDDS form, the compound can be applied in deeper layers of the skin and, when injected, can penetrate cell walls to act directly on cytoplasm. The product is currently in the development stage and has not been approved for use by the FDA or any foreign agency.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Vilacto Bio Inc.
The Seagram Building
375 Park Avenue, Suite 2607
New York City, NY 10152
Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com
Vilacto Bio Inc (OTCMKTS: VIBI) market activity and share price are trending higher, as the company inches closer to securing an essential patent for its lead compound. Canadian Intellectual Property Office approving a patent application for the company’s LACTOACTIVE molecule is the latest catalyst fuelling price action.
Yeah I bought big on the dips today and plan to continue. Good to see you here. Lets get this puppy back up over a dime by the end of the year. :)
They just dropped some huge news today also
LOL!!! Buy back in
TF you in here too. SWEET!! I got in today. LOL
Yeah I like this one a lot now. LOL. That news is great. Gives us time to load the boat before Summer and Fall. I plan to add on all dips. :)
ELECTRA HAS 917,000 followers
https://www.instagram.com/p/BuvdFPFhzT7/
6100 Likes already on her IG
products coming out in Summer and Fall.. That means load as many damn shares as you can before the launch LOL
OH DAMN!!!!!!
THIS NEWS IS VERY IMPRESSIVE
Vilacto Bio offering natural alternatives to strong drugs in the Psoriasis and diabetics market
Apr 9, 2019 | Company News | 0 comments
NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) — Denmark-based Vilacto Bio Inc. (OTC QB: VIBI) is happy to announce that the company has decided to introduce 2 new products and present them for the market later this summer/fall. The company will present one product for people with psoriasis and one product for people suffering from diabetes, especially skin issues related to diabetes.
The 2 new products are the result of a significant amount of testing and great customer feedback with the above-mentioned issues. Regarding psoriasis we have learned that patients with this condition are seeing results after a few days’ use. Furthermore, some patients have expanded the periods between regular medical treatments when they are using the Vilact skin cream with the patented ingredient Lactoactive.
But also, when it comes to diabetes, there has been overwhelming feedback. With the cooperation of Danish podiatrists, the Vilact skin cream has helped a large number of patients with issues related to diabetes, and in numerous cases has helped patients get of rid of complicated skin issues.
We believe the secret behind the success of these patients is the Lactoactive particles. The Lactoactive compound is a powerful mix of proteins, vitamins, grow factors and immune factors customized into Nanoparticles for better penetrating the skin and giving their effect, this effect is not only on the skin tissue but deeper as well. The company’s process creates nanoparticles and we believe that the ingredient increases the potency delivered to skin cells.
“We are hoping with the introduction of these new products that people suffering psoriasis and diabetes related skin disorders can have an alternative to the stronger drugs on the market – keeping in mind that what we get from nature sometimes can be more effective with less side effects,” said CEO Gert Andersen. “These products are also expected to have a huge benefit for the company and show the public that the company stands apart from the competition on skincare,” continued Mr. Andersen.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain “forward-looking” statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Vilacto Bio Inc.
The Seagram Building
375 Park Avenue, Suite 2607
New York City, NY 10152
Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com
I took a starter here today. I like the news :)